Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical ap... (

Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications

Date:3/27/2008

- Composition of Matter Patent Granted and Enforceable in 24 European

Countries - Competitors Precluded from Immediate Commercialization of Competitive

Products

LAVAL, QC, March 27 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) announces that the European Patent Office (EPO) granted on May 31st 2007 Neptune's composition of matter patent entitled "Natural Marine Source Phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications" (EP01417211B1) and that this patent has now been issued and validated in twenty-four European countries.

This patent is directed to the use of Neptune marine phospholipid and flavonoid compositions as a medicament for the prevention and treatment of multiple chronic health conditions, including coronary artery disease caused by hypercholesterolemia, peripheral vascular disease, neurodegenerative and other cognitive disorders.

"This composition of matter patent is a critical achievement that constitutes a key component for our commercial pharmaceutical development program," said Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Neptune's mission has always been the development of innovative pharmaceutical ingredients, and this patent is viewed as a vital element towards Neptune's pharmaceutical initiatives. Its enforcement is a major accomplishment and a step forward," she added.

As part of the EPO procedure, within a nine-month period following the date of granting of the European patent, a notice of opposition can be filed in writing with the EPO. In the case of Neptune, oppositions were filed by Norway-based Aker BioMarine and Israel-based Enzymotec. The opposition proceedings are a multi-year (5-7 year) procedure with the potential outcome of maintaining the patent, amending it or, in certain cases, revoking it. According to EPO regulations,
'/>"/>

1

GOOD

Page: 1 2 3
Related biology technology :

1. Neptune Technologies expands into medicinal markets in Asia Pacific
2. Neptune Technologies receives GRAS notification in the United States
3. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
6. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
7. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
8. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
9. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results

Post Your Comments:

Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical ap...( - Composition of Matter Patent Gra...)